Cethromycin versus Clarithromycin for Community-Acquired Pneumonia: Comparative Efficacy and Safety Outcomes from Two Double-Blinded, Randomized, Parallel-Group, Multicenter, Multinational Noninferiority Studies

English, Marci L.; Fredericks, Christine; Milanesio, Nancy A.; Rohowsky, Nestor; Xu, Zhenghu; Jenta, Tuah R.-J.; Flavin, Michael T.; Eiznhamer, David A.

doi:10.1128/aac.05596-11

Cited by 23 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two phase III non-inferiority studies have been performed comparing cethromycin with clarithromycin. Both studies met the non-inferiority endpoint in the treatment of community acquired pneumonia 51 . However, additional clinical trials are necessary before this agent is approved for clinical use 47 .…”

Section: How Would New Antibiotics Impact Favorably On Drug Resistance?mentioning

confidence: 96%

New antibiotic agents in the pipeline and how they can help overcome microbial resistance

2013

View full text Add to dashboard Cite

Bacterial resistance is a growing threat and yet few new antibiotics active against multi-resistant bacteria are being explored. A combination of falling profits, regulatory mechanisms and irrational and injudicious use of antibiotics has led to an alarming situation where some infections have no cure. In this article, we summarize the new developments that have been suggested to incentivize the pharmaceutical industries toward the field of infections. We also briefly mention the new compounds on the horizon and some newly approved compounds that might help us tide over this crisis.

show abstract

Section: How Would New Antibiotics Impact Favorably On Drug Resistance?mentioning

confidence: 96%

New antibiotic agents in the pipeline and how they can help overcome microbial resistance

2013

View full text Add to dashboard Cite

show abstract

“…The search for RCTs yielded 5,495 titles. After applying inclusion and exclusion criteria, 43 RCTs were included in the final analysis (Figure ): two trials of CAP‐C; three of mixed CAP‐C and CAP‐H, 20 of CAP‐H, two of mixed CAP‐H and HCAP, three of HCAP, six of HAP, five of VAP, and two of HAP and VAP . Two CAP‐H trials targeted a priori an elderly population …”

Section: Resultsmentioning

confidence: 99%

Participation of Elderly Adults in Randomized Controlled Trials Addressing Antibiotic Treatment of Pneumonia

Avni

Shiver-Ofer

Leibovici

et al. 2015

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…The entire V1B database containing 1 billion compounds is freely available via GitHub (https ://githu b.com/zinph / SIME). In our previous research, we compiled and studied eighteen experimentally confirmed bioactive macrolides (BMs) from different studies [1,[18][19][20][21][22][23][24][25] and extracted nine "common" and seven "rare" SMs from the scaffolds of 18 BMs (structures shown in Fig. 4 of [16]).…”

Section: Parameter Settings For V1bmentioning

confidence: 99%

SIME: synthetic insight-based macrolide enumerator to generate the V1B library of 1 billion macrolides

2020

View full text Add to dashboard Cite

We report on a new cheminformatics enumeration technology-SIME, synthetic insight-based macrolide enumerator-a new and improved software technology. SIME can enumerate fully assembled macrolides with synthetic feasibility by utilizing the constitutional and structural knowledge extracted from biosynthetic aspects of macrolides. Taken into account by the software are key information such as positions in macrolide structures at which chemical components can be inserted, and the types of structural motifs and sugars of interest that can be synthesized and incorporated at those positions. Additionally, we report on the chemical distribution analysis of the newly SIME-generated V1B (virtual 1 billion) library of macrolides. Those compounds were built based on the core of the Erythromycin structure, 13 structural motifs and a library of sugars derived from eighteen bioactive macrolides. This new enumeration technology can be coupled with cheminformatics approaches such as QSAR modeling and molecular docking to aid in drug discovery for rational designing of next generation macrolide therapeutics with desirable pharmacokinetic properties.

show abstract

Cethromycin versus Clarithromycin for Community-Acquired Pneumonia: Comparative Efficacy and Safety Outcomes from Two Double-Blinded, Randomized, Parallel-Group, Multicenter, Multinational Noninferiority Studies

Cited by 23 publications

References 34 publications

New antibiotic agents in the pipeline and how they can help overcome microbial resistance

New antibiotic agents in the pipeline and how they can help overcome microbial resistance

Participation of Elderly Adults in Randomized Controlled Trials Addressing Antibiotic Treatment of Pneumonia

SIME: synthetic insight-based macrolide enumerator to generate the V1B library of 1 billion macrolides

Contact Info

Product

Resources

About